Zomedica Reports Record Q1 Growth and Optimism
Company Announcements

Zomedica Reports Record Q1 Growth and Optimism

Zomedica Pharma (ZOM) has released an update.

Zomedica Corp. reported a robust start to 2024 with a 14% increase in first-quarter revenue to $6.3 million and a solid gross margin of 66%. The growth was attributed to a strong performance in both Therapeutic Devices and Diagnostics segments, with the company touting the period as its strongest first quarter ever. Despite a total cash usage of $9.6 million, Zomedica is optimistic about its expansion strategy and is on track to pursue profitability and significant revenue growth.

For further insights into ZOM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyZomedica says USEF names PulseVet as official Shock Wave Therapy Supplier
TheFlyZomedica presents Truforma BAW research
TheFlyZomedica increases manufacturing capacity at Georgia facility
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!